Emalex Biosciences will use the cash from its Series D financing to conduct a Phase 3 clinical trial for ecopipam, an experimental treatment for Tourette syndrome. Though there drugs are already available for Tourette, Emalex’s drug addresses a different central nervous system target that the biotech believes could offer an edge.
New company Areteia Therapeutics launched with up to $350 million in financing and an asthma drug candidate from Knopp Biosciences. That drug, dexpramipexole, previously failed a pivotal test in amyotrophic lateral sclerosis but more recent clinical testing found that the way the small molecule works has applications in eosinophilic asthma, a severe form of the respiratory disease.
Every wellness clinic is only as successful as the capabilities of its software. Here's where you can find the top-rated practice management solutions for med spas.
The study design is still being finalized, and the company is thus not yet divulging too many details. However, CEO David Daly said it would be significantly larger than the previous DETECT-A, multi-center and would include both men and women.